Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Michael R. McClung

Oregon Osteoporosis Center

Portland

OR 97213

USA

[email]@orost.com

Name/email consistency: high

[Claim this account]

Affiliations

Oregon Osteoporosis Center, Portland, OR 97213, USA. 2003 - 2013
Department of Medical Education, Providence Portland Medical Center, Portland, OR 97213, USA. 2004 - 2006
Providence Portland Medical Center, Portland, USA. 2006
Department of Medical Education, Providence Portland Medical Center and the Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 651, USA. 2003

References

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. McClung, M.R., Balske, A., Burgio, D.E., Wenderoth, D., Recker, R.R. Osteoporos. Int (2013) [Pubmed]
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. McClung, M.R., Lewiecki, E.M., Geller, M.L., Bolognese, M.A., Peacock, M., Weinstein, R.L., Ding, B., Rockabrand, E., Wagman, R.B., Miller, P.D. Osteoporos. Int (2013) [Pubmed]
Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. McClung, M.R., Zanchetta, J.R., Racewicz, A., Roux, C., Benhamou, C.L., Man, Z., Eusebio, R.A., Beary, J.F., Burgio, D.E., Matzkin, E., Boonen, S., Delmas, P. Osteoporos. Int (2013) [Pubmed]
A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. McClung, M.R., Benhamou, C.L., Man, Z., Tlustochowicz, W., Zanchetta, J.R., Eusebio, R., Balske, A.M., Matzkin, E., Olszynski, W.P., Recker, R., Delmas, P.D. Calcif. Tissue Int. (2013) [Pubmed]
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. McClung, M.R., Boonen, S., Törring, O., Roux, C., Rizzoli, R., Bone, H.G., Benhamou, C.L., Lems, W.F., Minisola, S., Halse, J., Hoeck, H.C., Eastell, R., Wang, A., Siddhanti, S., Cummings, S.R. J. Bone Miner. Res. (2012) [Pubmed]
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. McClung, M.R., Miller, P.D., Brown, J.P., Zanchetta, J., Bolognese, M.A., Benhamou, C.L., Balske, A., Burgio, D.E., Sarley, J., McCullough, L.K., Recker, R.R. Osteoporos. Int (2012) [Pubmed]
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. McClung, M.R., Bolognese, M.A., Sedarati, F., Recker, R.R., Miller, P.D. Bone (2009) [Pubmed]
Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. McClung, M., Miller, P., Recknor, C., Mesenbrink, P., Bucci-Rechtweg, C., Benhamou, C.L. Obstet. Gynecol (2009) [Pubmed]
The clinical and epidemiologic consequences of redefining treatment criteria: who should be treated?. McClung, M. Salud. Publica. Mex (2009) [Pubmed]
Role of RANKL inhibition in osteoporosis. McClung, M. Arthritis Res. Ther. (2007) [Pubmed]
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. McClung, M., Recker, R., Miller, P., Fiske, D., Minkoff, J., Kriegman, A., Zhou, W., Adera, M., Davis, J. Bone (2007) [Pubmed]
Do current management strategies and guidelines adequately address fracture risk? McClung, M.R. Bone (2006) [Pubmed]
Denosumab in postmenopausal women with low bone mineral density. McClung, M.R., Lewiecki, E.M., Cohen, S.B., Bolognese, M.A., Woodson, G.C., Moffett, A.H., Peacock, M., Miller, P.D., Lederman, S.N., Chesnut, C.H., Lain, D., Kivitz, A.J., Holloway, D.L., Zhang, C., Peterson, M.C., Bekker, P.J. N. Engl. J. Med. (2006) [Pubmed]
Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. McClung, M.R. Curr. Osteoporos. Rep (2006) [Pubmed]
Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. McClung, M.R., Siris, E., Cummings, S., Bolognese, M., Ettinger, M., Moffett, A., Emkey, R., Day, W., Somayaji, V., Lee, A. Menopause (2006) [Pubmed]
Bisphosphonates. McClung, M. Arq. Bras. Endocrinol. Metabol (2006) [Pubmed]
The relationship between bone mineral density and fracture risk. McClung, M.R. Curr. Osteoporos. Rep (2005) [Pubmed]
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. McClung, M.R., San Martin, J., Miller, P.D., Civitelli, R., Bandeira, F., Omizo, M., Donley, D.W., Dalsky, G.P., Eriksen, E.F. Arch. Intern. Med. (2005) [Pubmed]
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. McClung, M.R., Wasnich, R.D., Recker, R., Cauley, J.A., Chesnut, C.H., Ensrud, K.E., Burdeska, A., Mills, T. J. Bone Miner. Res. (2004) [Pubmed]
Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. McClung, M.R., Wasnich, R.D., Hosking, D.J., Christiansen, C., Ravn, P., Wu, M., Mantz, A.M., Yates, J., Ross, P.D., Santora, A.C. J. Clin. Endocrinol. Metab. (2004) [Pubmed]
Parathyroid hormone for the treatment of osteoporosis. McClung, M. Obstet. Gynecol. Surv (2004) [Pubmed]
Bisphosphonates. McClung, M.R. Endocrinol. Metab. Clin. North Am. (2003) [Pubmed]
The menopause and HRT. Prevention and management of osteoporosis. McClung, M.R. Best Pract. Res. Clin. Endocrinol. Metab. (2003) [Pubmed]
Use of highly potent bisphosphonates in the treatment of osteoporosis. McClung, M. Curr. Osteoporos. Rep (2003) [Pubmed]

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.